8-K: CV Sciences Reports Fiscal Year-End 2024 Financial Results, Showing Improved Gross Margins and Reduced Operating Expenses

CV Sciences, Inc. announced its fiscal year-end 2024 financial results, highlighting a slight revenue decrease but significant improvements in gross margins and reduced operating expenses.

Summary

• CV Sciences, Inc. reported a revenue of $15.7 million for fiscal year 2024, slightly down from $16.0 million in 2023.
• The company's gross margin improved to 45.6% for fiscal year 2024, compared to 44.3% in the previous year.
• Operating expenses decreased by 5.4% to $9.4 million for fiscal year 2024, excluding a benefit from the reversal of accrued payroll taxes.
• The adjusted EBITDA loss significantly improved to $0.8 million for fiscal 2024 from $2.3 million in 2023.
• The company's cash balance at year-end was $0.5 million, compared to $1.3 million at the end of 2023.
• CV Sciences launched the +PlusHLTH line of cannabinoid-free supplements and the Lunar Fox plant-based food line.
• The company retained Maxim Group LLC as a financial advisor and investment banker.
• Fourth quarter revenue increased 2.2% to $3.9 million compared to the same period in the prior year.
• The company generated an operating loss of $2.2 million in fiscal 2024, compared to an operating income of $3.4 million in 2023, mostly due to the reversal of accrued payroll taxes of $6.2 million in 2023, improved gross margins and reduced operating expenses.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue is slightly down, improvements in gross margin, reduced operating expenses, and new product launches suggest a positive trajectory. The company's focus on innovation and cost-efficient execution is also encouraging.

Positives

• Gross margin improved to 45.6% for fiscal year 2024, up from 44.3% in 2023.
• Operating expenses were reduced by 5.4% to $9.4 million for fiscal year 2024.
• Adjusted EBITDA loss improved significantly to $0.8 million for fiscal 2024, compared to a $2.3 million loss in 2023.
• B2C sales increased in fiscal 2024 by $0.1 million or 1.6% because of higher volume, despite lower digital marketing advertisement.
• The company launched the +PlusHLTH line of cannabinoid-free supplements and the Lunar Fox plant-based food line.
• The company entered into a strategic partnership with Chewy to offer their best selling pet products on www.chewy.com.
• The company acquired Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry, based in Colorado.

Negatives

• Revenue decreased slightly to $15.7 million for fiscal year 2024 from $16.0 million in 2023.
• The company's cash balance decreased to $0.5 million at year-end, compared to $1.3 million at the end of 2023.
• The company generated an operating loss of $2.2 million in fiscal 2024, compared to an operating income of $3.4 million in 2023, mostly due to the reversal of accrued payroll taxes of $6.2 million in 2023, improved gross margins and reduced operating expenses.

Risks

• The company faces a challenging market and regulatory environment for its core business.
• The company's B2B sales were impacted by the patchwork of state regulations for CBD.
• The company's future performance is subject to risks, uncertainties, and assumptions that are difficult to predict.

Future Outlook

The company anticipates further gross margin improvements in 2025 and looks forward to organic growth with new product development. They will continue to pursue additional M&A opportunities to improve top-line revenue, profitability, and shareholder value.

Management Comments

• 'We are pleased with our fiscal year 2024 results. Revenues for our core business remained stable around the $4 million range per quarter throughout 2024 despite a challenging market and regulatory environment,' stated Joseph Dowling, Chief Executive Officer of CV Sciences.
• 'With our recent acquisitions and new product innovations, we believe that we are nicely positioned to grow our revenue in 2025.'
• 'Our fiscal 2024 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow.'

Industry Context

CV Sciences operates in the consumer wellness industry, specializing in hemp extracts, nutraceuticals, and plant-based foods. The company is the top-selling hemp extract brand in the natural products market, according to SPINS. They are expanding into the plant-based food market with the launch of Lunar Fox, targeting the growing vegan category.

Comparison to Industry Standards

• The document mentions that CV Sciences' +PlusCBD branded products are the top-selling hemp-extract brand in the natural products market, according to SPINS.
• This indicates a leading position in the hemp extract segment compared to competitors in the natural product retail sales channel.
• The company's expansion into plant-based foods with Lunar Fox aligns with the global vegan food market trend, which is expected to grow significantly by 2030.
• Comparable companies in the hemp extract and CBD space include Charlotte's Web and cbdMD, while plant-based food competitors include Beyond Meat and Impossible Foods.

Stakeholder Impact

• Shareholders may see potential for improved profitability and growth due to cost reductions and new product lines.
• Employees may benefit from a more stable and growing company.
• Customers will have access to new and innovative products in the hemp extract and plant-based food categories.
• Suppliers may see increased demand as the company expands its product offerings.

Next Steps

• The company intends to continue building an efficient and cost-effective consumer products platform.
• The company intends to continue to evaluate inbound and outbound merger, sale, acquisition or other opportunities.
• The company will continue to pursue additional M&A opportunities in the near future to improve top-line revenue, profitability and shareholder value.

Key Dates

Keywords

CV Sciences, Financial Results, Hemp Extracts, CBD, Supplements, Plant-Based Foods, Gross Margin, EBITDA, Revenue